Comparative Pharmacology
Head-to-head clinical analysis: LOW OGESTREL 28 versus MIBELAS 24 FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOW OGESTREL 28 versus MIBELAS 24 FE.
LOW-OGESTREL-28 vs MIBELAS 24 FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol and norgestrel inhibit ovulation via suppression of gonadotropins (LH, FSH); increase viscosity of cervical mucus, impairing sperm penetration; alter endometrial structure, reducing implantation likelihood.
Combination hormonal contraceptive: ethinyl estradiol suppresses LH and FSH, primarily inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity, increasing cervical mucus viscosity and altering endometrial morphology.
One tablet (norgestrel 0.3 mg/ethinyl estradiol 30 mcg) orally once daily at the same time each day for 28 days, with 21 active tablets followed by 7 inactive tablets.
One tablet orally once daily for 24 days followed by 4 placebo tablets. Each tablet contains 75 mcg desogestrel and 0.02 mg ethinyl estradiol.
None Documented
None Documented
Norgestrel: ~45 hours (terminal). Ethinyl estradiol: ~13 hours (terminal). Steady-state achieved within 5-7 days.
Drospirenone: ~30 hours; Ethinyl estradiol: ~17 hours. Steady-state reached after ~10 days for drospirenone.
Renal 50-60% as metabolites, fecal 40-50% via biliary elimination. Ethinyl estradiol undergoes enterohepatic recirculation.
Drospirenone: 40-50% renal as metabolites, <10% unchanged; ~50% fecal. Ethinyl estradiol: ~40% renal, 60% fecal.
Category C
Category C
Oral Contraceptive
Oral Contraceptive